Drug-Drug Interactions (DDIs) may hamper the functionalities of drugs, and in the worst scenario, they may lead to adverse drug reactions (ADRs). Predicting all DDIs is a challenging and critical problem. Most existing computational models integrate drug-centric information from different sources and leverage them as features in machine learning classifiers to predict DDIs. However, these models have a high chance of failure, especially for the new drugs when all the information is not available. This paper proposes a novel Hypergraph Neural Network (HyGNN) model based on only the SMILES string of drugs, available for any drug, for the DDI prediction problem. To capture the drug similarities, we create a hypergraph from drugs' chemical substructures extracted from the SMILES strings. Then, we develop HyGNN consisting of a novel attention-based hypergraph edge encoder to get the representation of drugs as hyperedges and a decoder to predict the interactions between drug pairs. Furthermore, we conduct extensive experiments to evaluate our model and compare it with several state-of-the-art methods. Experimental results demonstrate that our proposed HyGNN model effectively predicts DDIs and impressively outperforms the baselines with a maximum ROC-AUC and PR-AUC of 97.9% and 98.1%, respectively.
翻译:药物-药物相互作用(DDI)可能会妨碍药物的功能,在最坏的情况下,它们可能导致药物反应不良(ADRs) 。预测所有DDI是一个具有挑战性和关键的问题。大多数现有的计算模型综合了不同来源的以药物为中心的信息,并将它们作为机器学习分类器的特征加以利用,以预测DDI。然而,这些模型极有可能失败,特别是在没有所有信息的情况下新药物。本文建议一种新型超光谱神经网络(HyGNNN)模型,它仅以可用于任何药物的SMILES系列药物为基础,用于DDI预测问题。为了捕捉药物的相似性,我们制作了从SMILES链提取的药物化学子结构的高级图象。然后,我们开发了HYGNNN(H)模型,其中包括一种新型的以注意力为基础的高光谱边缘编码器,以获得药物作为高屏障和分解器来预测药物配方之间相互作用的描述。此外,我们进行了广泛的实验,以评价我们的模型并将其与几种最先进的方法进行比较。实验结果表明,我们提议的HIGNAF9和RA模型分别预测了98-AFAU的98和9。